ViroMed's Plasmid DNA Facility Buy Addresses Key Potential US Regulatory Hurdle
Executive Summary
ViroMed, which is progressing Phase III clinical trials for its gene therapy VM202 in the US, has acquired a plasmid DNA manufacturing facility in San Diego, a move that will enable the South Korean biotech to provide stable supplies of the product if approved, and addressing a major uncertainty for gene therapies seeking regulatory approval from the FDA.
You may also be interested in...
Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
Interview: ViroMed On Pricing, Manufacturing World’s First Broadly Used Gene Therapy
The head of global business strategy at ViroMed, one of the gene therapy companies nearing the commercial stage in the US, talks exclusively to Scrip about the South Korean biotech’s strategies, including for pricing and manufacturing, which are emerging as key considerations for developers.
Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.